Cipla acquires 4 nutrition products from Wanbury for Rs 89 crore

Published On 2020-02-10 06:28 GMT   |   Update On 2020-02-10 06:28 GMT

New Delhi: Homegrown pharma firm Cipla on Saturday announced the acquisition of nutrition products portfolio from Wanbury Ltd. The company has acquired 4 brands namely CPink, CDense, Productiv and Folinine to further strengthen its presence in women's health portfolio. 

The nutraceutical products, to be sold under the 4 umbrella brands, would address various health needs for conditions arising due to nutritional deficiencies or insufficiencies, Cipla said in a regulatory filing.

This includes supplements such as multivitamins, multimineral and antioxidants for adolescent girls, pregnant and lactating women, women going through menopause and for male and female reproductive health, it said.

Through this newly acquired portfolio, the company shall be catering to a wide range of patient's needs including nutritional deficiencies, bone health and sexual health, it said.

The above molecules previously commercialized by Wanbury have a market size of Rs 3,100 crore in India with sales value of Rs 59.6 crore.

Also Read: Cipla Q3 Revenue Up By 13pc At Rs 4371 Crore

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News